Acadian Asset Management
RLMD icon

Acadian Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Acadian Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76M Sell
543,394
-169,146
-24% -$1.18M ﹤0.01% 886
2026
Q1 		$4.96M Buy
712,540
+185,822
+35% +$879K 0.01% 718
2025
Q4 		$2.54M Sell
526,718
-55,825
-10% -$187K ﹤0.01% 848
2025
Q3 		$1.17M Sell
582,543
-36,936
-6% -$35.4K ﹤0.01% 1018
2025
Q2 		$371K Sell
619,479
-608,449
-50% -$312K ﹤0.01% 1198
2025
Q1 		$329K Hold
1,227,928
– – ﹤0.01% 1162
2024
Q4 		$636K Buy
1,227,928
+41,476
+3% +$101K ﹤0.01% 1021
2024
Q3 		$3.84M Sell
1,186,452
-6,881
-0.6% -$22.3K 0.01% 567
2024
Q2 		$3.58M Buy
1,193,333
+12,147
+1% +$43.9K 0.01% 590
2024
Q1 		$5.49M Sell
1,181,186
-1,639
-0.1% -$7.9K 0.02% 447
2023
Q4 		$4.89M Buy
1,182,825
+10,102
+0.9% +$29.9K 0.02% 463
2023
Q3 		$3.51M Sell
1,172,723
-48,676
-4% -$145K 0.01% 541
2023
Q2 		$3M Hold
1,221,399
– – 0.01% 587
2023
Q1 		$2.75M Buy
1,221,399
+121,060
+11% +$417K 0.01% 625
2022
Q4 		$3.83M Buy
+1,100,339
New +$9.66M 0.02% 520

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management's RLMD Position: Q2 2026 in Review

Acadian Asset Management reduced its Relmada Therapeutics (RLMD) stake by 24% in Q2 2026, selling an estimated $1.18M and leaving 543,394 shares worth $3.76M. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Acadian Asset Management first reported a position in RLMD in Q4 2022 and has held it in 15 quarters since. The position peaked at $5.49M in Q1 2024. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Acadian Asset Management held 543,394 shares of Relmada Therapeutics worth $3.76M as of Q2 2026.
  • Acadian Asset Management sold 169,146 Relmada Therapeutics shares in Q2 2026, an estimated $1.18M.
  • Relmada Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #886 holding.
  • Acadian Asset Management first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Acadian Asset Management's Relmada Therapeutics position peaked at $5.49M in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.